The May issue of Ophthalmology, the  journal of the American Academy of Ophthalmology, includes a surprising,  first report on  increasing rates of age-related macular degeneration  (AMD) among Asians, and describes an innovative "bypass" laser surgery  that may help many people with central retinal vein occlusion (CRVO)  avoid serious vision loss.
Are Asians as Vulnerable to AMD as Caucasians?
A major review by Tien Yi Wong, MD, MPH, PhD, and Singapore Eye  Research Institute colleagues concludes that Asians may be just as  susceptible to age-related macular degeneration as Caucasians. Asians  have long been considered a low risk group for AMD, which is a leading  cause of vision loss in older Caucasians. Since the number of elderly  people is increasing in Asia, Dr. Wong's study suggests that health  systems there need to prepare for an onslaught of AMD.
Pooling results from nine standardized-diagnosis studies in five  Asian populations (Japan, China, South Korea, India and Singapore), Dr.  Wong's group confirmed prevalence of early-stage AMD as 6.8 percent and  late-stage as 0.56 percent, comparable to Caucasians at 8.8 percent and  0.59 percent, respectively. All rates pertain to people aged 40 to 79  years. Also, among those with late AMD, the "wet" (neovascular) form  appeared to be more prevalent in Asians than in whites. Asian men were  more likely to develop late AMD than white men and much more likely than  Asian women.
The researchers speculate that Asian men may be more susceptible to  polypoidal choroidal vasculopathy (PCV), abnormal development of blood  vessels in the deeper layers of the eye. Whether PCV is a sub-type of  AMD or a separate disorder remains controversial; it is also unclear  whether PCV responds well to medications that inhibit abnormal blood  vessel growth (anti-vascular endothelial growth factor drugs such as  Avastin and Lucentis) that help many wet AMD patients keep their vision.
"Future studies should evaluate whether there are 'Asian forms' of  AMD and discern other racial/ethnic differences in Asian  susceptibility," Dr. Wong said."Our meta-analysis could not adjust for  important risk factors like smoking, common among many Asian men; nor  did this study include all relevant Asian racial/ethnic groups," he  added.
"Bypass" May Lead to Vision Gains for CRVO Patients
Central retinal vein occlusion (CRVO) affects one to four percent of  Americans older than 40 and very often causes severe vision loss,  including "legal blindness" (20/200 vision). While current treatments  reduce CRVO symptoms such as macular edema-swelling of the center of the  eye's light-sensitive retina-none address the underlying problem, the  blocked retinal vein. Ian L. McAllister, MD, Lions Eye Institute,  Australia, and his research team took direct aim at the problem, using  lasers to create a "bypass" around the constricted retinal vein with the  aim of restoring near-normal blood flow to the retina.
In three-quarters of the eyes treated the "bypass" was successful,  and patients achieved significant vision gains by the 18 month  follow-up. This study was also the first prospective, randomized trial  to compare the bypass approach, called laser-induced chorioretinal  venous anastomosis (L-CRA), with conventional treatment.
L-CRAs were successfully created in 76.4 percent of the 58 patients  in whom the procedure was attempted. Overall, bypass-treated patients  achieved significantly better visual acuity and were more likely to gain  20/40 vision (the legal standard for drivers in many countries) than  were control group patients. Bypass patients were significantly less  likely to have moderate or severe vision loss. While about 18 percent of  L-CRA-treated patients developed a significant complication-abnormal blood vessel growth at the surgery site-the  researchers report that due to close monitoring and effective  management, negative consequences from this and other complications were  minimal.
"The risk of complications from L-CRA should be weighed against the  substantial vision loss faced by CRVO patients with standard  treatments," Dr. McAllister said. "In future studies of L-CRA, optical  coherence tomography (not widely available when our study began) would  be another useful outcome measure for L-CRA effectiveness," he added.
Provided by American Academy of Ophthalmology
http://newscri.be/link/1089328
 
Related articles:
Macular   Degeneration  - New guide! Tips, treatments, resources, and  questions to ask. - www.afb.org/seniorsite
Stop   Macular Degeneration  - Regain Lost Vision with Dr. Todd's Proven  no-Surgery or Drugs Approach - www.BetterVision.com
No comments:
Post a Comment